ViaNautis
ViaNautis is a pioneering biotechnology company focused on developing genetic nanomedicines using its proprietary polyNaut® technology. This innovative platform utilizes advanced polymer materials and machine learning to deliver nucleic acid therapeutics with high precision to specific sites in the body. Established in 2018, ViaNautis is building a robust pipeline of products aimed at addressing previously untreatable diseases through safe and targeted delivery methods. The company operates from state-of-the-art facilities in Cambridge, UK, and is positioned to lead in the genetic medicine market with its unique approach to therapeutic delivery.
ViaNautis
ViaNautis is a pioneering biotechnology company focused on developing genetic nanomedicines using its proprietary polyNaut® technology. This innovative platform utilizes advanced polymer materials and machine learning to deliver nucleic acid therapeutics with high precision to specific sites in the body. Established in 2018, ViaNautis is building a robust pipeline of products aimed at addressing previously untreatable diseases through safe and targeted delivery methods. The company operates from state-of-the-art facilities in Cambridge, UK, and is positioned to lead in the genetic medicine market with its unique approach to therapeutic delivery.
TL;DR
Founded: 2018 (UCL spin-out)
Headquarters: Cambridge, UK
Technology: polyNaut® polymer-based nanovesicles for genetic delivery
Latest financing: Series A $25M (Nov 13, 2023)
Notable partners/investors: 4BIO Capital, BGF, UCB Ventures, Eli Lilly, Cystic Fibrosis Foundation
Company Overview
Problem Domain
Targeted delivery of genetic medicines (cell and gene therapy delivery across biological barriers).
Founded
2018
Industry
Biotechnology
Funding Track Record
$25,000,000
Participation from the Cystic Fibrosis Foundation, Eli Lilly and existing investors
Investor Signal
“Strategic participation from Eli Lilly and funding led by life-science-focused investors”